Aim of the work: The aim of our study was to assess the serum levels of transforming growth factor-b1 (TGF-b1) in Egyptian systemic lupus erythematosus (SLE) patients in order to determine whether these levels are associated with disease activity and organ damage.
Introduction
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease with variable clinical presentation. SLE can affect all organs and the involvement of major organs can be life threatening. The exact pathological mechanisms of SLE remain elusive, and the etiology of SLE is known to be multifactorial [1] . Measuring organ damage in SLE is important with special concern to juvenile-onset patients to allow for designing new treatments that improve control of disease activity and minimize the development of irreversible damage. The kidney appeared to be commonly involved, especially in males, indicating the importance of regular screening for early and appropriate management [2] .
Several key player factors play a significant role in the pathogenesis of SLE such as cytokine overproduction [3, 4] , oxidative stress [5] and apoptosis [6] . Comorbidities as metabolic syndrome [7] , dyslipidemia and atherosclerosis [8] could lead to functional disability, impaired quality of life and significantly affect the disease activity and damage. Many proinflammatory cytokines were found to play a prominent role in the pathogenesis of SLE; while anti-inflammatory cytokines, such as interleukin-4 (IL-4), IL-10 and TGF-b1 were important to preserve a balance in the cytokine milieu [9] . In a study on Egyptian SLE patients, serum levels of IL-4 were significantly lower while both IL-17 and interferon-gamma (IFN-c) were significantly higher in SLE patients and the latter 2 cytokines were considered as biomarkers of renal activity [10] . Similarly, studies on other proinflammatory and central factors as IL-18 [11] , B-lymphocyte stimulator (BLyS) [12] , resistin [13] , matrix metalloproteinase [14] and growth arrest specific protein-6 (gas6) [15] , showed that they may have a pathogenic role in the development of SLE and play a crucial role in the development, triggering of activity and severity in lupus nephritis.
The transforming growth factor b (TGF-b) family of cytokines encompasses three closely related members: TGF-b1, TGF-b2, and TGF-b3. Lymphocytes and monocytes produce the b1 isoform of this cytokine which exerts a major immune regulatory function [16] . TGF-b1 is the most potent naturally occurring immunosuppressant; it plays a fundamental role in controlling proliferation and the fate of cells through apoptosis. TGF-b1 is an important negative regulator of B cell differentiation and proliferation, inhibiting the production of most immunoglobulin iso-types [17] . It also serves as a co-stimulatory factor in the development of T cells with down-regulatory activities [18] . TGF-b1 might play a dual role during the development and progression of immune-mediated inflammatory diseases. TGF-b1 production by lymphocytes is reduced in SLE, this might predispose to autoreactive T cell activation and autoantibody production. In autoimmune diseases, infiltration of target organs, such as kidneys, with T cells or deposition of autoantibodycontaining immune complexes causes early inflammatory lesions that trigger the local production of anti-inflammatory cytokines such as TGF-b1 by macrophages and renal mesangial cells to counter inflammation [19] . The enhanced TGF-b1 production in tissues induces local fibrogenesis and ultimately causes fulminant organ damage [20] . So any treatment for SLE that involved manipulation of TGF-b1 would need to be approached with caution considering effects on the cytokine network as a whole [21] .
The aim of our study was to assess the serum levels of TGF-b1 in 70 Egyptian patients with SLE and 60 healthy subjects. Serum levels of TGF-b1 were related to disease-related variables in order to determine whether serum levels of TGF-b1 might associate to disease activity and organ damage in SLE.
Patients and methods
This is a case-control study, in which 70 SLE patients diagnosed according to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria [22] , were studied. All patients were recruited from the Rheumatology and Rehabilitation Department, Kasr Al Ainy hospital Cairo University. Approval for the study was obtained from the Rheumatology and Rehabilitation and also the Clinical Pathology Departments (according to the WMA Declaration of Helsinki). All patients received a thorough explanation of the study design and aims, and were provided with written informed consent. Sixty healthy subjects served as controls and were matched to the cases as closely as possible for age (with mean of 31.37 ± 6.5 years old), sex (52 females and 8 males), and ethnic group.
Disease activity was assessed with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [23] . Disease damage was recorded according to the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index [24] . The grades of disease activity were defined as SLEDAI 0 = quiescent disease, SLEDAI 1-10 = moderate activity, and SLEDAI >10 = high disease activity. The cut-off for organ damage was SLICC 0 = no organ damage, SLICC 1-3 = moderate organ damage, and SLICC >3 = severe organ damage. SLE patients were divided into different groups according to the following criteria denoting renal damage; 24-h urinary protein over 3.5 gm/dl or not; glomerular filtration rate (GFR) less than 50 ml/min or not; serum creatinine over 1.2 mg/dl or not.
In attempt to elucidate the importance of TGF-b1 for the development of SLE, we measured serum levels of TGF-b1 in 70 patients with SLE and in 60 healthy controls.
Measurement of serum TGF-b1 concentration
Peripheral blood samples were obtained from all subjects. Serum samples were collected and stored frozen at À20 C until assayed. The concentrations of TGF-b1 protein in the serum samples were measured by quantitative sandwich enzyme linked immunosorbent assay (ELISA) technique, using commercially available kits (Human TGF-beta1 Platinum ELISA Bioscience Cat No BMS249/4). The results were calculated by reference to the standard curve and expressed as pg/ml.
Statistical analysis: All data were tabulated, statistically analyzed. The data were coded and entered using the software SPSS (Statistical package for social science) version 15. The data were summarized using descriptive statistics: mean, standard deviation, minimal and maximum values for quantitative variables and number and percentage for qualitative values.
Statistical differences between groups were tested using Chi Square test for qualitative variables, independent sample t test for quantitative normally distributed variables while non parametric Mann Whitney test was used for quantitative variables which are not normally distributed. The correlation between serum TGFB1 level and disease-related variables was assessed by Spearman coefficient of correlation. p values < 0.05 were considered statistically significant.
Results
The study included 70 SLE patients with a mean age of 28.04 ± 9.3 years. They were 65 females and 5 males. Demographic data, medications received and disease-related variables of SLE patients are shown in Table 1 .
In this case-control study, the serum level of TGF b1 in SLE patients ranged from 170 to 1900 pg/ml with a mean of 875.8 ± 292.2 pg/ml, while its level in the control group ranged from 670 to 1900 pg/ml with a mean of 1140 ± 301 pg/ml. Comparison between levels of serum TGF b1 in SLE patients and the control group showed a statistically significant difference, being lower in SLE patients (p < 0.001).
Correlating serum TGF-b1 to disease-related variables in SLE patients, showed a statistically significant correlation with hemoglobin (Hb) and platelet counts and negatively with serum creatinine, urea, erythrocyte sedimentation rate (ESR) and total SLEDAI score. No significant correlation was detected between serum TGF-b1 and SLICC/ACR damage index ( Table 2) .
On comparison of the serum TGF-b1 levels according to renal damage, a statistically significant difference was found between patients with GFR <50 ml/min and those with >50 ml/min (p = 0.038) ( Fig. 1) . No statistically significant difference was found between serum TGF-b1 in patients with 24-h urine protein over 3.5 gm/dl and patients with <3.5 gm/dl (p = 0.65). A statistically significant lower TGF-b1 was found in patients with serum creatinine >1.2 mg/dl compared to those <1.2 mg/dl (p = 0.003) ( Fig. 2 and Table 3 ).
Comparison between SLE patients with moderate SLEDAI versus those with higher SLEDAI as regards serum TGF-b1 levels (954.4 ± 327.6 and 779.8 ± 230.5 pg/ml, respectively) showed a significant difference (p = 0.025). Comparison between SLE patients with no organ damage and those with moderate organ damage (SLICC/ACR score 1-3) as regards serum TGF-b1 levels (929.1 ± 310.4 and 804.6 ± 253.7, respectively) showed no significant difference (p = 0.088).
We found lower serum levels of TGF-b1 in patients with malar rash, vasculitis, arthritis nephritis and cerebritis than in those without these clinical features but the difference was not statistically significant (data not shown).
Discussion
TGF-b1 knockout mice developed a SLE-like disorder with various autoantibodies, suggesting the possible involvement of TGF-b1 in the pathogenesis of SLE [25] . Preliminary human studies suggest that TGF-b1 expression in SLE may be dysregulated [26] .
The present study showed a statistically significant difference between patients with SLE and the healthy subjects regarding serum TGF-b1 levels, being lower in patients. This is in concordance to other studies [16, 27] that found that serum levels of TGF-b1 were significantly reduced in patients with SLE compared with levels in healthy controls. They attributed their findings to impaired production of TGF-b1 by lymphocytes isolated from SLE patients. Another study done by Xing et al. [28] revealed that the concentration of serum TGF-b1 was markedly decreased in SLE patients in parallel with reduced peripheral T regulatory cells. Although Kohut et al. [29] in their study showed that TGF-b1 mRNA production is defective in T and B cells isolated from SLE patients' peripheral blood, they found slightly increased serum TGF-b1 levels in SLE patients than in controls. They attributed these paradoxical findings by the potential production of TGF-b1 by monocytes and other non lymphoid cells. In another study on Egyptian rheumatoid arthritis patients, there was a twofold increase in the TGF-b level proving a disturbance in the cytokine milieu in favor of inflammation and drawing attention to its importance in the pathogenesis of this other autoimmune disease [9] . TGF-b1 in SLE patients and its relation to organ damage and disease activity S51
Our results showed a significant correlation between serum TGF-b1 and both Hb and platelet counts. While there was a significant negative correlation between it and serum creatinine, urea, ESR and total SLEDAI score. This is in concordance to the findings of other studies that revealed a significantly negative correlation between serum TGF-b1 and SLEDAI score [30, 31] . Also Jin and his colleagues [16] showed a significant correlation between serum TGF-b1 and white blood cells counts and platelet counts, while there was a significant negative correlation between it and ESR. They suggested that the strong correlation between TGF-b1 levels and blood platelet numbers might indicate that the platelets might be another reservoir of importance for TGF-b1 levels in patients with SLE. They also suggested that the inverse correlation between TGF-b1 and ESR might indicate that low level of TGF-b1 might be a valuable tool for determining disease activity.
In the present study malar rash was present in 72.9%, arthritis in 81.4%, vasculitis in 17.1%, lupus nephritis in 78.6% and cerebritis in 32.5%. The mean SLEDAI was 10.39 ± 7.2 and SLICC was 0.67 ± 0.93. These findings are comparable and in harmony with those found in another Egyptian study [32] on a cohort of SLE patients where the mucocutaneous manifestations were found in 72.5%, arthritis in 67.5%, nephritis in 79.5, neuropsychiatric in 38.5% and SLEDAI was 9.95 ± 8.2 however; vasculitis was present in 3.5% and SLICC was much higher (2.7 ± 2.2).
In our study, SLE patients were divided into different subgroups regarding disease activity (SLEDAI) and organ damage (SLICC). The levels of serum TGF-b1 were significantly lower in patients with high disease activity than in patients with moderate activity. Lower levels of serum TGF-b1 were found in patients with organ damage than in patients without. These were in agreement with the results of another study that found lower serum TGF-b1 levels in patients with high disease activity and severe organ damage [16] .
We found significantly lower levels of serum TGF-b1 in patients with renal damage as presented by those with a GFR <50 ml/min and those with a serum creatinine >1.2 mg/dl. This was in agreement with the results of Jin et al. [16] who found a significantly lower level of serum TGF-b1 in patients with renal damage (24-h urine protein >3.5 g/dl; GFR <50 ml/min, creatinine >90 mmol/l). In SLE patients, the expression and signaling of the TGF-b1 system might be activated in a local inflamed organ, for example in the kidneys, although systemic levels are decreased. This was demonstrated by Saxena et al. [19] who measured TGF-b1 concentrations in kidneys and urine of lupus mice and found that they correlated with the extent of chronic kidney disease.
Currently, the treatment for SLE has evolved from conventional drugs such as corticosteroids and immunosuppressants to biologic agents. Various therapeutic agents targeting different cytokines have been developed to treat SLE. The efficacy of these agents is believed to depend on specific disease condition, different organs involved, and timing of medication, indicating a spatial and temporal variety of cytokine expression in SLE, which provide challenge for cytokine-targeted therapy for SLE and necessitate further investigation [33] .
It is noteworthy to mention that performing this study on a larger number of patients longitudinally and taking into consideration the gender differences, medications received and antiphospholipid status are suggested in the future and considered as limitations of this work.
We concluded that in SLE lowered serum TGF-b1 level might be a feature of systemic immune dysfunction, which might be associated to disease susceptibility, activity, organ damage and might have a role in the pathogenesis of renal involvement in those patients. However, further studies are recommended to evaluate the use of serum TGF-b1 as a non-invasive marker for assessment of activity and organ damage and to determine its plausible role as a therapeutic target of interest in SLE. GFR: glomerular filtration rate, TGF: Transforming growth factor. * p < 0.05 is considered statistically significant.
